Goldman Sachs Boosts Target on Hologic (HOLX) Ahead of Tomo Catalyst, Says Use Options

Goldman Sachs reiterated its Buy rating and raised its price target on Hologic (NASDAQ: HOLX) from $22 to $24 ahead of physician commentary on tomosynthesis at the European Congress of Radiology this weekend.

"We estimate $0.05 of EPS upside for every 1000 bp conversion in HOLX’s tomo
upgradable installed base," the analyst comments. "While we maintain our outlook for flat HC utilization, we see sufficient new product catalysts and OUS opportunities to support modest growth in HOLX’s other businesses."

The firm is recommending Buying the March $22 calls for $0.20 ahead of the ECR conference.

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $20.73 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Donnelley Financial Solutions (DFIN) PT Raised to $72 at B.Riley
• PROG Holdings (PRG) PT Raised to $35 at Loop Capital
• Goldman Sachs Upgrades The TJX Companies (TJX) to Buy, 'best-in-class operator'